Dr. Eng on Ongoing Studies for BRAF-Mutant CRC

Cathy Eng, MD

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing trials investigating treatment for patients with BRAF-mutant colorectal cancer (CRC).

The SWOG 1406 trial looked at a control arm of irinotecan and cetuximab (Erbitux) plus or minus vemurafenib (Zelboraf) with a primary endpoint of progression-free survival (PFS). The study was positive for PFS, but there was crossover allowed, so it was not positive for overall survival, explains Eng.

According to Eng, it was an eye-opening study as it provided a BRAF inhibitor to patients as part of a clinical trial.
Printer Printing...